Prevalence and clinical profile of inflammatory bowel disease patients with small bowel cancer: A retrospective analysis of National Inpatient Sample data.

484 Background: Small bowel cancer (SBC) accounts for around 3% of all gastrointestinal malignancies, with inflammatory bowel disease (IBD) recognized as a risk factor. Our study aims to evaluate the IBD prevalence in SBC patients, annual trends, and associated demographics, comorbidities, and healthcare burden. Methods: Adults (≥18 years) with SBC were queried from the National Inpatient Sample (NIS 2016-2022). The presence of IBD was further identified via prevalidated ICD-10 codes. We estimated the prevalence of IBD among SBC patients along with the yearly trend. Baseline patient demography and comorbidities were compared among both IBD and non-IBD cohorts. All analyses were performed via STATA 18. 0, adjusting for the stratification, cluster, and weight of the NIS. Results: We found 67345 SBC patients which included 2360 cases (3. 5%) of IBD, of which 83. 47% had Crohn’s disease (CD) and 16. 53% had ulcerative colitis (UC). The highest annual prevalence was noted in 2019 (4. 21%), with a nadir in 2021 (2. 9%). Yearly trends fluctuated as illustrated in Table 1 and were not statistically significant (ptrend = 0. 229). IBD patients were younger (mean age 62. 37 vs 66. 81 years, p = <0. 01), with fewer patients having preexisting hypertension (HTN) (43. 43% vs 59. 78%, p = <0. 01), diabetes (15. 89% vs 26. 23%, p = <0. 01), dyslipidemia (20. 34% vs 36. 37%), obesity (6. 36% vs 10. 56%), peptic ulcer disease (PUD) (0. 636% vs 3. 93%), long term aspirin use (5. 09% vs 9. 22%), congestive heart failure (CHF) (6. 99% vs 11. 53%), alcohol use (0. 85% vs 2. 39%), (p<0. 05 throughout). The history of pulmonary embolism or thromboembolism was higher among IBD patients (12. 29% vs 8. 13%, p = <0. 01). Most patients were insured with Medicare (47. 46% of IBD vs 57. 51% of non-IBD cohort, p = <0. 01) and racially classified as White (86. 36% of IBD cohort vs 64. 83% of non-IBD cohort). Socioeconomic differences were noted as a higher proportion of non-IBD patients belonged to the lowest income quartiles (27. 02%), whereas a greater percentage of IBD cohorts belonged to 51-75th percentile (31. 48%). Around 50. 21% of IBD and 50. 89% of non-IBD patients had metastasis (p = 0. 781). An estimated 12. 71% of IBD and 15. 73% of non-IBD patients used palliative care (p=0. 086). IBD patients had a longer stay (9. 83 vs. 8. 63 days, p = 0. 016) but comparable mean hospital charge (137260 vs. 118985, p = 0. 076) and all-cause in-hospital death (6. 36% vs 5. 55%, p = 0. 449). Conclusions: IBD cohort comprised younger patients who had fewer comorbidities. Continued screening, monitoring, and education of IBD patients remains essential. Additionally, the socioeconomic disparities observed among non-IBD patients in our study warrant further investigation. Prevalence of IBD among small bowel cancer admissions. Year 2016 2017 2018 2019 2020 2021 2022 Prevalence of IBD cases (%) 3. 56 2. 93 4. 14 4. 21 3. 35 2. 90 3. 47